A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.

ABSTRACT: BACKGROUND:Despite effective therapies, outcomes for diffuse large B-cell lymphoma (DLCBL) remain heterogeneous in older individuals due to comorbid diseases and variations in disease biology. METHODS:Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, the authors conducted a multistate survival analysis of 11,780 patients with DLBCL who were aged ≥65 years at the time of diagnosis (2002-2009). Cox proportional hazards models were used to specify the impact of prognostic factors on overall survival and cause-specific deaths, and the Aalen-Johansen estimator was used to project the course of DLBCL over time with or without standard therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). RESULTS:Advanced age (hazard ratio [HR]

SUBMITTER: Caglayan C 

PROVIDER: S-EPMC6509004 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature